Trabectome: Definition, Uses, and Clinical Overview

Trabectome Introduction (What it is)

Trabectome is a surgical device used to treat certain types of glaucoma by improving fluid outflow from the eye.
It is commonly used in minimally invasive glaucoma surgery (MIGS) performed from inside the eye.
The goal is to lower intraocular pressure (IOP), which is a major risk factor for glaucoma progression.
It is often considered in people whose glaucoma is not adequately controlled with drops alone.

Why Trabectome used (Purpose / benefits)

Trabectome is used to help reduce elevated intraocular pressure in glaucoma. In glaucoma, pressure-related and pressure-independent factors can damage the optic nerve (the nerve that carries visual information to the brain). Lowering IOP is one of the main ways clinicians aim to slow glaucoma-related optic nerve damage.

Trabectome is designed to address a common outflow problem in open-angle glaucoma: resistance to aqueous humor drainage at the trabecular meshwork. Aqueous humor is the clear fluid continuously produced inside the front part of the eye. If this fluid does not drain efficiently, pressure can rise.

In general terms, potential benefits of a Trabectome-based procedure may include:

• Improving the eye’s natural drainage pathway rather than creating an external filtering bleb (a fluid pocket under the conjunctiva)
• Reducing IOP and/or reducing the medication burden in selected patients (results vary by clinician and case)
• Being performed through a small internal approach (ab interno), commonly associated with faster visual recovery than more extensive glaucoma surgeries in many patients (recovery varies)
• Being combined with cataract surgery in some cases, allowing treatment of two conditions in one operative setting when appropriate

Trabectome is not a “vision correction” procedure like LASIK. Its purpose is pressure management to help reduce the risk of ongoing glaucoma damage.

Indications (When ophthalmologists or optometrists use it)

Trabectome is typically considered in scenarios such as:

• Primary open-angle glaucoma with IOP above the individualized target despite medications and/or laser therapy
• Pseudoexfoliative glaucoma with an open angle (case selection varies)
• Pigmentary glaucoma with an open angle (case selection varies)
• Patients undergoing cataract surgery who also have mild to moderate glaucoma and may benefit from an additional IOP-lowering step
• Patients who have difficulty with adherence to multiple glaucoma drops, experience side effects, or want to reduce drop burden (goals vary)
• Earlier surgical intervention in glaucoma when a clinician prefers an internal, trabecular outflow approach before more invasive filtering surgeries

Optometrists generally do not perform Trabectome procedures, but may participate in detection, referral, and postoperative monitoring in co-managed care settings (scope varies by location and practice model).

Contraindications / when it’s NOT ideal

Trabectome may be less suitable, not feasible, or less effective in situations such as:

• Angle-closure glaucoma or narrow angles where the trabecular meshwork cannot be safely accessed without other interventions
• Extensive peripheral anterior synechiae (scar tissue that closes parts of the drainage angle), limiting access to trabecular tissue
• Certain secondary glaucomas where the main resistance is not at the trabecular meshwork (for example, outflow pathway scarring beyond Schlemm’s canal; suitability varies by clinician and case)
• Advanced glaucoma where a clinician believes a lower target IOP is needed than trabecular procedures typically achieve (targets vary by patient)
• Eyes with significant corneal opacity or issues that prevent adequate visualization of the drainage angle during surgery
• Active eye infection or uncontrolled ocular inflammation, where elective intraocular surgery is usually deferred
• Situations where a different procedure is preferred due to prior surgical history (for example, scarring patterns or previous angle surgeries; approach varies)

In some of these cases, another approach—such as laser, a different MIGS procedure, or more traditional filtering surgery—may be considered.

How it works (Mechanism / physiology)

Trabectome is used to remove a strip of trabecular meshwork and the inner wall of Schlemm’s canal from inside the eye. This is often described as an ab interno trabeculectomy, meaning the work is performed internally through a small corneal incision rather than from the outside of the eye.

Relevant anatomy (explained simply)

• Aqueous humor: Fluid produced behind the iris that flows through the pupil into the front chamber of the eye.
• Anterior chamber angle: The junction where the cornea and iris meet; this is where the eye’s main drainage structures sit.
• Trabecular meshwork: A spongy, sieve-like tissue that is a major site of resistance to aqueous outflow in open-angle glaucoma.
• Schlemm’s canal: A circular channel that collects fluid after it passes through the trabecular meshwork and routes it to collector channels and episcleral veins.

Mechanism in practical terms

By removing part of the trabecular meshwork, Trabectome aims to reduce resistance at the main “bottleneck” of outflow in many open-angle glaucomas. This can allow aqueous humor to access Schlemm’s canal and downstream channels more directly, potentially lowering IOP.

Onset, duration, and reversibility

• Onset: IOP effects are generally assessed over the early postoperative period and then over subsequent follow-ups; the trajectory can vary by individual healing and preoperative factors.
• Duration: Trabecular outflow procedures can have lasting effects, but long-term control depends on many factors, including disease severity, angle anatomy, and downstream outflow function.
• Reversibility: The removal of trabecular tissue is not reversible in the treated segment. However, further glaucoma treatments (additional MIGS, laser, filtering surgery, medications) may still be possible if needed.

Trabectome Procedure overview (How it’s applied)

Trabectome is part of a surgical procedure performed by an ophthalmologist in an operating room or ambulatory surgery center. The exact steps and protocols vary by surgeon and patient.

A high-level workflow often looks like this:

1. Evaluation / exam
   – Diagnosis and staging of glaucoma, review of IOP history, optic nerve assessment, and visual field testing
   – Examination of the drainage angle (gonioscopy) to confirm that the angle anatomy is suitable
   – Discussion of goals (pressure lowering, medication reduction, or both), acknowledging that outcomes vary by clinician and case

2. Preparation
   – Preoperative measurements and routine surgical planning
   – Use of local anesthesia with sedation in many cases (anesthesia choice varies)
   – Sterile preparation of the eye

3. Intervention
   – A small corneal incision is made to access the anterior chamber
   – The surgeon views the angle structures using a special lens
   – Trabectome is used to treat a segment of trabecular meshwork to improve outflow
   – The procedure may be performed alone or combined with cataract surgery when indicated

4. Immediate checks
   – The surgeon confirms stable eye pressure, a formed anterior chamber, and appropriate wound sealing
   – Early postoperative IOP is monitored because short-term fluctuations can occur after glaucoma procedures

5. Follow-up
   – Postoperative visits assess IOP, inflammation, corneal clarity, and overall recovery
   – Medication plans and follow-up schedules vary; some patients continue some glaucoma drops depending on response and clinician preference

This is an overview, not a step-by-step guide for patients to follow.

Types / variations

Trabectome refers to a specific device and technique, but it is used in a few common clinical “variations” based on surgical context:

• Standalone Trabectome
  Performed as an independent glaucoma procedure when cataract surgery is not being done at the same time.

• Combined cataract surgery + Trabectome
  Performed during the same session as cataract removal and intraocular lens implantation in patients who have both cataract and glaucoma. The combined approach may be selected to address visual blur from cataract and pressure management from glaucoma, recognizing that results vary.

• Extent of trabecular treatment
  Surgeons may treat different arc lengths of the trabecular meshwork depending on anatomy, visualization, and surgical plan (extent varies by clinician and case).

• Position within the broader MIGS category
  Trabectome is one of several angle-based MIGS options. Other MIGS procedures may use implants (stents), cutting devices, dilation of Schlemm’s canal, or viscodilation. The choice depends on anatomy, target IOP, surgeon experience, and patient factors.

Pros and cons

Pros:

• Targets the trabecular meshwork, a key site of outflow resistance in many open-angle glaucomas
• Typically performed through a small internal incision (ab interno approach)
• Does not rely on an external filtering bleb in the way traditional trabeculectomy does
• Can be combined with cataract surgery in selected patients
• Often allows future glaucoma treatments if needed (medications, laser, or other surgeries), depending on the overall clinical picture
• May reduce medication burden for some patients (varies by clinician and case)

Cons:

• Not appropriate for all glaucoma types, especially angle-closure or eyes with significant angle scarring
• IOP lowering may be insufficient for some advanced cases requiring very low target pressures (targets vary)
• Postoperative IOP fluctuations can occur, requiring monitoring
• Visual recovery and comfort can vary, and temporary inflammation is common after intraocular procedures
• As with any intraocular surgery, there are risks such as bleeding in the front of the eye, infection, or corneal issues; risk profiles vary
• Outcomes depend on downstream outflow pathway function; if Schlemm’s canal or collector channels are compromised, effect may be limited

Aftercare & longevity

Aftercare following Trabectome is generally focused on monitoring healing, inflammation, and pressure stability. The specifics of postoperative drops, visit frequency, and activity restrictions vary by clinician and case, and they may differ when Trabectome is combined with cataract surgery.

Factors that can influence outcomes and longevity include:

• Glaucoma type and severity: Mild to moderate open-angle disease is a common setting, while advanced disease may require different strategies.
• Baseline IOP and target IOP: Starting pressure and the pressure goal influence how “successful” a given level of lowering is considered.
• Angle anatomy and scarring: Prior inflammation, trauma, or synechiae can affect access and effectiveness.
• Downstream outflow health: Schlemm’s canal and collector channels must be able to carry fluid away; this varies between individuals.
• Medication adherence and follow-up: Ongoing monitoring matters because glaucoma is chronic and can progress silently.
• Ocular surface health and comorbidities: Dry eye, blepharitis, and other conditions can affect comfort and drop tolerance; systemic conditions may affect healing.

Longevity is best thought of as variable: some patients maintain good pressure control for years, while others may need additional medications or procedures over time.

Alternatives / comparisons

Trabectome sits within a broader glaucoma management spectrum. Comparisons are high-level because the “best” option depends on disease stage, anatomy, and clinician goals.

• Observation / monitoring
  In ocular hypertension or very early glaucoma, clinicians may monitor without immediate surgery. This is more common when risk is lower and the optic nerve is stable.

• Medications (eye drops)
  Drops can lower IOP through reduced aqueous production and/or increased outflow. They are non-surgical but require long-term adherence and may cause side effects or ocular surface irritation in some patients.

• Laser therapy (e.g., selective laser trabeculoplasty, SLT)
  SLT targets the trabecular meshwork to improve outflow without an incision. It may be used before surgery, after surgery, or as an alternative depending on response and clinical strategy.

• Other MIGS (angle-based or canal-based)
  Options include trabecular micro-bypass stents, canal scaffolds, goniotomy-style procedures using different instruments, and canal dilation approaches. These share the goal of improving physiologic outflow but differ in mechanism (implant vs tissue removal vs dilation), cost structure, and surgeon preference.

• Traditional filtering surgery (trabeculectomy) and tube shunts
  These procedures can achieve lower IOP targets in many cases but generally involve more intensive postoperative management and different risk profiles. They are often considered when glaucoma is advanced or when other treatments have not achieved adequate control.

The choice among these approaches is individualized and depends on the balance between needed IOP reduction and acceptable risk/management intensity.

Trabectome Common questions (FAQ)

Q: Is Trabectome a surgery or a device?
Trabectome is the name of a device used during a glaucoma surgery performed from inside the eye. The procedure is commonly categorized as MIGS because it targets the drainage angle through a small internal approach.

Q: Does Trabectome improve vision?
Trabectome is intended to lower intraocular pressure, not to sharpen vision directly. Some people notice vision changes only if the procedure is combined with cataract surgery or if postoperative blur resolves as the eye heals.

Q: Is the procedure painful?
Many patients report pressure or mild discomfort rather than significant pain, but experiences vary. Local anesthesia is commonly used, and postoperative irritation can occur as the eye heals.

Q: How long does it take to recover?
Early recovery is often measured in days to weeks, with ongoing pressure stabilization assessed over follow-up visits. Recovery timing depends on whether the procedure is combined with cataract surgery, baseline eye health, and individual healing responses.

Q: How long do the results last?
Trabecular tissue removal is permanent in the treated area, but long-term pressure control can change over time. Longevity depends on glaucoma severity, downstream drainage function, and whether additional treatments are needed.

Q: Is Trabectome considered “safe”?
All eye surgeries carry risks, and safety is best understood as a risk–benefit decision tailored to the individual. Trabectome is generally viewed as less invasive than traditional filtering surgery, but complications can still occur and must be monitored.

Q: Will I still need glaucoma drops after Trabectome?
Some patients can reduce the number of drops, while others continue one or more medications. Whether drops are needed depends on the pressure response and the target IOP set by the clinician.

Q: When can someone drive or return to screen time after the procedure?
Timing varies based on vision clarity, comfort, and clinician instructions after the postoperative check. Many patients resume normal screen use relatively soon, but driving should wait until vision is stable and legally adequate.

Q: What does Trabectome cost?
Cost depends on the care setting, insurance coverage, geographic region, and whether it is combined with cataract surgery. Because pricing and coverage vary widely, clinics often provide individualized estimates.

Q: Can Trabectome be repeated or followed by other glaucoma surgeries?
The treated trabecular segment cannot be “undone,” and repeating the same approach may or may not be useful depending on anatomy. However, many patients can still undergo additional glaucoma treatments later, such as medications, laser, other MIGS, or more traditional surgeries if needed.